Miyazaki H, Nambu K, Matsunaga Y, Hashimoto M
Eur J Drug Metab Pharmacokinet. 1979;4(4):199-206. doi: 10.1007/BF03189427.
Following oral administration of [14C]loperamide hydrochloride in 1 mg/kg to rats, plasma levels of radioactivity reached maximum at 4 hrs and decreased with a half-life of 4.1 hrs. Radioactivity in 96-hr feces accounted for 95% of the dose, with 30% associated with unchanged drug, while that in urine only 3.5%. Radioactivity in 48-hr bile accounted for 42% of the dose associated entirely with metabolites. 3% of the dose was found at the level of the enterohepatic cycles. These findings show that about 70% of the dose with absorbed by intestine, the target tissue of the drug, a portion (30%) of which was excreted back into intestinal cavity after demethylation, while the remaining 40% transferred to liver by which it was extracted mostly, metabolized extensively and excreted largely into bile, as supported by in vitro demethylating activity in gut segments but none in gut contents, and by in situ marked hepatic extraction of the drug. Main metabolic pathways involved are described.
给大鼠口服1mg/kg的[14C]盐酸洛哌丁胺后,血浆放射性水平在4小时达到峰值,随后以4.1小时的半衰期下降。96小时粪便中的放射性占给药剂量的95%,其中30%与未变化的药物有关,而尿液中的放射性仅占3.5%。48小时胆汁中的放射性占给药剂量的42%,且完全与代谢物有关。3%的给药剂量出现在肠肝循环水平。这些发现表明,约70%的给药剂量被药物的靶组织肠道吸收,其中一部分(30%)在去甲基化后被排泄回肠腔,而其余40%转移到肝脏,大部分被肝脏摄取、广泛代谢并大量排泄到胆汁中,这得到了肠段体外去甲基化活性(但肠内容物中无此活性)以及药物原位显著肝脏摄取的支持。文中描述了主要的代谢途径。